Humoral responses in coronavirus disease 2019 (COVID-19) are often of limited durability,
as seen with other human coronavirus epidemics. To address the underlying etiology, we …

The Ad26.COV2.S vaccine 1 , 2 – 3 has demonstrated clinical efficacy against symptomatic
COVID-19, including against the B.1.351 variant that is partially resistant to neutralizing …

The development of a portfolio of COVID-19 vaccines to vaccinate the global population
remains an urgent public health imperative 1 . Here we demonstrate the capacity of a subunit …

SARS-CoV-2 mRNA vaccines confer robust protection against COVID-19, but the emergence
of variants has generated concerns regarding the protective efficacy of the currently …

Abstract Development of an effective tuberculosis (TB) vaccine has suffered from an incomplete
understanding of the correlates of protection against Mycobacterium tuberculosis (Mtb). …

Adjuvanted soluble protein vaccines have been used extensively in humans for protection
against various viral infections based on their robust induction of antibody responses. Here, …

Neutrophils, the most abundant white blood cell, play a critical role in anti-pathogen immunity
via phagocytic clearance, secretion of enzymes and immunomodulators, and the release …

There is a great need for the development of vaccines that induce potent and long-lasting
protective immunity against SARS-CoV-2. Multimeric display of the antigen combined with …

A combination of vaccination approaches will likely be necessary to fully control the severe
acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic. Here, we show that …

Despite the robust immunogenicity of SARS-CoV-2 mRNA vaccines, emerging data have
revealed enhanced neutralizing antibody and T cell cross-reactivity among individuals that …